Radiopharmaceuticals: A Brief Overview of Basic Pharmacological Parameters
Abstract
Radiopharmaceuticals are combinations of two main components, a pharmaceutical component that targets specific moieties, and a radionuclide component that acts through spontaneous degradation for diagnostic, therapeutic purposes, or both simultaneously known as theranostics. By combining diagnostic and therapeutic methods, radiotheranostics play an important role in reducing radiation dosages for patients, increasing treatment effectiveness, controlling side effects, improving patient outcomes, and reducing overall treatment costs. Despite the diagnostic and therapeutic roles, radiopharmaceuticals are beneficial for assessing prognosis, disease progression and possibility of recurrences, treatment planning strategies, and assessing response to treatment. The most incredible role of radiopharmacy is establishing new radiopharmaceuticals to better target and tolerated agents for imaging and treatment in a clinic. These approaches are supported by nuclear medicine non-invasive procedures. It is crucial for radiopharmaceuticals that drug delivery occurs in a highly selective and sensitive manner to minimize the potential radiation risk to patients. This report will provide an overview of the recent progress in radiopharmaceuticals for diagnosis and therapy, including the latest radiotheranostic tracers, key concerns within the field, and future trends and prospects. Additionally, the available and useful radiopharmaceuticals are categorized into separate tables based on their specific characteristics. Presenting information in table format enhances organization and makes the data more understandable and accessible for users. This structured approach allows users to quickly locate relevant information, compare different radiopharmaceuticals, and grasp essential details at a glance. By utilizing tables, we ensure that critical information is not only easy to read but also effectively highlights the unique attributes of each radiopharmaceutical, ultimately improving the decision-making process for healthcare professionals.
1- Buck A Rhodes and Barbara Y Croft, Basics of radiopharmacy. Mosby, (1978).
2- Farid A Badria, "Radiopharmaceuticals: On-Going Research for Better Diagnosis, Therapy, Environmental, and Pharmaceutical Applications." Radiopharmaceuticals: Current Research for Better Diagnosis and Therapy, p. 3, (2022).
3- George Sgouros, Lisa Bodei, Michael R McDevitt, and Jessie R Nedrow, "Radiopharmaceutical therapy in cancer: clinical advances and challenges." Nature Reviews Drug Discovery, Vol. 19 (No. 9), pp. 589-608, (2020).
4- Filipe Boccato Payolla, Antonio Carlos Massabni, and Chris Orvig, "Radiopharmaceuticals for diagnosis in nuclear medicine: A short review." Eclética Química, Vol. 44 (No. 3), pp. 11-19, (2019).
5- Craig W Lindsley, Christa E Müller, and Salvatore Bongarzone, "Diagnostic and therapeutic radiopharmaceuticals." Vol. 5, ed: ACS Publications, (2022), pp. 835-37.
6- Teresa A O’Sullivan and Curtis G Jefferson, "A review of strategies for enhancing clarity and reader accessibility of qualitative research results." American Journal of Pharmaceutical Education, Vol. 84 (No. 1), p. 7124, (2020).
7- Vladimir Drozdovitch et al., "Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960–2010." Health physics, Vol. 108 (No. 5), pp. 520-37, (2015).
8- Buck A Rhodes and Barbara Y Croft, "Basics of radiopharmacy." (No Title), (1978).
9- Michael F L'Annunziata, Radioactivity: introduction and history, from the quantum to quarks. Elsevier, (2016).
10- Seyed K Imam, "Molecular nuclear imaging: the radiopharmaceuticals." Cancer biotherapy & radiopharmaceuticals, Vol. 20 (No. 2), pp. 163-72, (2005).
11- George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, Gabriel Andrieș, Călin Căinap, and Vasile Chiș, "Radiopharmaceuticals for PET and SPECT imaging: A literature review over the last decade." International journal of molecular sciences, Vol. 23 (No. 9), p. 5023, (2022).
12- Ora Israel et al., "Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence." European journal of nuclear medicine and molecular imaging, Vol. 46pp. 1990-2012, (2019).
13- Adriano Duatti, "Review on 99mTc radiopharmaceuticals with emphasis on new advancements." Nuclear medicine and biology, Vol. 92pp. 202-16, (2021).
14- Joseph Lau, Etienne Rousseau, Daniel Kwon, Kuo-Shyan Lin, François Bénard, and Xiaoyuan Chen, "Insight into the Development of PET Radiopharmaceuticals for Oncology." Cancers, Vol. 12 (No. 5), p. 1312, (2020).
15- Terence J O’Brien et al., "Comparative study of 99mTc-ECD and99mTc-HMPAO for peri-ictal SPECT: qualitative and quantitative analysis." Journal of Neurology, Neurosurgery & Psychiatry, Vol. 66 (No. 3), pp. 331-39, (1999).
16- Erhard Suess, Sigismund Huck, Hans Reither, Heide Hörtnagl, and Peter Angelberger, "Uptake mechanism of technetium-99m-d, 1-HMPAO in cell cultures of the dissociated postnatal rat cerebellum." Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, Vol. 33 (No. 1), pp. 108-14, (1992).
17- Seok Rye Choi et al., "Correlation of amyloid PET ligand florbetapir F 18 (18F-AV-45) binding with β-amyloid aggregation and neuritic plaque deposition in postmortem brain tissue." Alzheimer Disease and Associated Disorders, Vol. 26 (No. 1), p. 8, (2012).
18- Jaya Shukla and Bhagwant Rai Mittal, "Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy." Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India, Vol. 30 (No. 4), p. 295, (2015).
19- Cheng-Han Wu, Bang-Hung Yang, Yuan-Hwa Chou, Shyh-Jen Wang, and Jyh-Cheng Chen, "Effects of 99mTc-TRODAT-1 drug template on image quantitative analysis." PLoS One, Vol. 13 (No. 3), p. e0194503, (2018).
20- Vera Artiko et al., "Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC." Nuclear Medicine Review, Vol. 19 (No. 2), pp. 99-103, (2016).
21- Steven M Larson, "Mechanisms of localization of gallium-67 in tumors." in Seminars in nuclear medicine, (1978), Vol. 8: Elsevier, pp. 193-203.
22- Heinz O Hirzel et al., "Thallium-201 scintigraphy in complete left bundle branch block." The American journal of cardiology, Vol. 53 (No. 6), pp. 764-69, (1984).
23- Archi Agrawal, Venkatesh Rangarajan, Sneha Shah, Ameya Puranik, and Nilendu Purandare, "MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies." The British journal of radiology, Vol. 91 (No. 1091), p. 20180103, (2018).
24- Werner Langsteger, Martin Heinisch, and Ignac Fogelman, "The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast." in Seminars in nuclear medicine, (2006), Vol. 36: Elsevier, pp. 73-92.
25- Clemens Kratochwil et al., "68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer." Journal of Nuclear Medicine, Vol. 60 (No. 6), pp. 801-05, (2019).
26- Padmaja Yalamanchili et al., "Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes: a novel PET myocardial imaging agent." Journal of Nuclear Cardiology, Vol. 14pp. 782-88, (2007).
27- John O Prior et al., "Quantification of myocardial blood flow with 82 Rb positron emission tomography: clinical validation with 15 O-water." European journal of nuclear medicine and molecular imaging, Vol. 39pp. 1037-47, (2012).
28- Jan H Rüschoff et al., "What’s behind 68 Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns." European journal of nuclear medicine and molecular imaging, Vol. 48pp. 4042-53, (2021).
29- Xiang Li et al., "[68 Ga] Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery." European journal of nuclear medicine and molecular imaging, Vol. 46pp. 1616-25, (2019).
30- George Sgouros, "Radiopharmaceutical therapy." Health physics, Vol. 116 (No. 2), p. 175, (2019).
31- Attila Keresztes, Attila Borics, and Csaba Tömböly, "Therapeutic and diagnostic radiopharmaceuticals." (2015).
32- Nasir Abbas, Helen Heyerdahl, Øyvind S Bruland, Jørgen Borrebæk, Jahn Nesland, and Jostein Dahle, "Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab." EJNMMI research, Vol. 1 (No. 1), pp. 1-12, (2011).
33- Narges K Tafreshi et al., "Development of targeted alpha particle therapy for solid tumors." Molecules, Vol. 24 (No. 23), p. 4314, (2019).
34- Albert Jang, Ayse T Kendi, Geoffrey B Johnson, Thorvardur R Halfdanarson, and Oliver Sartor, "Targeted Alpha-Particle Therapy: A Review of Current Trials." International journal of molecular sciences, Vol. 24 (No. 14), p. 11626, (2023).
35- Kwamena E Baidoo, Kwon Yong, and Martin W Brechbiel, "Molecular pathways: targeted α-particle radiation therapy." Clinical Cancer Research, Vol. 19 (No. 3), pp. 530-37, (2013).
36- Matt Shirley and Paul L McCormack, "Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases." Drugs, Vol. 74pp. 579-86, (2014).
37- Fable Zustovich and Francesca Fabiani, "Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases." Critical reviews in oncology/hematology, Vol. 91 (No. 2), pp. 197-209, (2014).
38- Jon L Aro, Stephen I Dinning, Eugene Y Leung, and Lionel S Zuckier, "Safe Use of Radium-223 Dichloride (223RaCl2) Across a Wide Range of Clinical Scenarios, Incorporating a 10-year Single-Institution Radiation Safety Experience." Journal of Medical Imaging and Radiation Sciences, Vol. 50 (No. 4), pp. S36-S40, (2019).
39- Malick Bio Idrissou, Alexandre Pichard, Bryan Tee, Tibor Kibedi, Sophie Poty, and Jean-Pierre Pouget, "Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide." Pharmaceutics, Vol. 13 (No. 7), p. 980, (2021).
40- Abdelhamid H Elgazzar, The pathophysiologic basis of nuclear medicine. Springer Science & Business Media, (2006).
41- Diane S Abou et al., "Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade." Journal of Nuclear Medicine, Vol. 62 (No. 12), pp. 1751-58, (2021).
42- Philippa J Cheetham and Daniel P Petrylak, "Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection." Oncology, Vol. 26 (No. 4), p. 330, (2012).
43- Nasim Vahidfar, Elisabeth Eppard, Saeed Farzanehfar, Anna Yordanova, Maryam Fallahpoor, and Hojjat Ahmadzadehfar, "An impressive approach in nuclear medicine: Theranostics." PET clinics, Vol. 16 (No. 3), pp. 327-40, (2021).
44- Nasim Vahidfar, Ayuob Aghanejad, Hojjat Ahmadzadehfar, Saeed Farzanehfar, and Elisabeth Eppard, "Theranostic advances in breast cancer in nuclear medicine." International journal of molecular sciences, Vol. 22 (No. 9), p. 4597, (2021).
45- Cristina Barca et al., "Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy." Pharmaceuticals, Vol. 15 (No. 1), p. 13, (2021).
46- Jonathan Strosberg et al., "Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors." New England Journal of Medicine, Vol. 376 (No. 2), pp. 125-35, (2017).
47- Ute Hennrich and Matthias Eder, "[177Lu] Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer." Pharmaceuticals, Vol. 15 (No. 10), p. 1292, (2022).
48- Irene Virgolini et al., "Procedure guidelines for pet/ct tumour imaging with 68 Ga-dota-conjugated peptides: 68 Ga-dota-toc, 68 Ga-dota-noc, 68 Ga-dota-tate." European journal of nuclear medicine and molecular imaging, Vol. 37pp. 2004-10, (2010).
49- Ute Hennrich and Martina Benešová, "[68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging." Pharmaceuticals, Vol. 13 (No. 3), p. 38, (2020).
50- Wallace Jones, Kelly Griffiths, Pedro C Barata, and Channing J Paller, "PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy." Cancers, Vol. 12 (No. 6), p. 1367, (2020).
51- Nikhil Mayor et al., "Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option." BJU international, Vol. 126 (No. 5), pp. 525-35, (2020).
52- Nasim Vahidfar, Maryam Fallahpoor, Saeed Farzanehfar, Ghasemali Divband, and Hojjat Ahmadzadehfar, "Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer." Journal of Radioanalytical and Nuclear Chemistry, Vol. 322pp. 237-48, (2019).
53- Thomas Lindner, Frederik L Giesel, Clemens Kratochwil, and Sebastian E Serfling, "Radioligands targeting fibroblast activation protein (FAP)." Cancers, Vol. 13 (No. 22), p. 5744, (2021).
54- Marko Magdi Abdou Sidrak et al., "Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review." International journal of molecular sciences, Vol. 24 (No. 4), p. 3863, (2023).
55- Liang Zhao et al., "Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review." Theranostics, Vol. 12 (No. 4), p. 1557, (2022).
56- Muhsin H Younis, Xiaoli Lan, and Weibo Cai, "PET with a 68Ga-Labeled FAPI Dimer: Moving Toward Theranostics." Journal of Nuclear Medicine, Vol. 63 (No. 6), p. 860, (2022).
57- Emran Askari, Sara Harsini, Nasim Vahidfar, Ghasemali Divband, and Ramin Sadeghi, "177Lu-EDTMP for metastatic bone pain palliation: A systematic review and meta-analysis." Cancer biotherapy & radiopharmaceuticals, Vol. 36 (No. 5), pp. 383-90, (2021).
58- José Carlos Dos Santos et al., "Development of novel PSMA ligands for imaging and therapy with copper isotopes." Journal of Nuclear Medicine, Vol. 61 (No. 1), pp. 70-79, (2020).
59- Maija Radzina et al., "Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?" EJNMMI radiopharmacy and chemistry, Vol. 8 (No. 1), p. 27, (2023).
60- Yuriko Mori, Katharina Dendl, Jens Cardinale, Clemens Kratochwil, Frederik L Giesel, and Uwe Haberkorn, "FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease." Radiology, Vol. 306 (No. 2), p. e220749, (2023).
61- Yizhen Pang et al., "PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study." Journal of Nuclear Medicine, Vol. 64 (No. 3), pp. 386-94, (2023).
62- Manish Ora et al., "Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions." Journal of Nuclear Medicine, (2023).
63- Rahul V Parghane and Sandip Basu, "PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects." Expert Review of Anticancer Therapy, Vol. 23 (No. 9), pp. 959-75, (2023).
64- Vishnu Murthy et al., "Prognostic value of end-of-treatment PSMA PET/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis." Journal of Nuclear Medicine, Vol. 64 (No. 11), pp. 1737-43, (2023).
65- Maija Radzina et al., "Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 10 (No. 2), p. 106, (2020).
66- Ali Afshar-Oromieh et al., "Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18 F-choline-based PET/CT for the diagnosis of recurrent prostate cancer." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41pp. 11-20, (2014).
67- Lena Koller et al., "Preclinical Comparison of the 64Cu-and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga] Ga-AMTG PET/CT." Journal of Nuclear Medicine, Vol. 64 (No. 10), pp. 1654-59, (2023).
68- Yanqing Zheng et al., "The value of targeting cxcr4 with 68ga-pentixafor pet/ct for subtyping primary aldosteronism." The Journal of Clinical Endocrinology & Metabolism, Vol. 109 (No. 1), pp. 171-82, (2024).
69- Kambiz Rahbar et al., "Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study." Journal of Nuclear Medicine, Vol. 64 (No. 4), pp. 574-78, (2023).
70- Siju C George and E James Jebaseelan Samuel, "Developments in 177Lu-based radiopharmaceutical therapy and dosimetry." Frontiers in Chemistry, Vol. 11(2023).
71- Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, and Melpomeni Fani, "Evaluation of a new 177Lu-labeled somatostatin analog for the treatment of tumors expressing somatostatin receptor subtypes 2 and 5." Molecules, Vol. 25 (No. 18), p. 4155, (2020).
72- Wael Jalloul et al., "Targeted alpha therapy: all we need to know about 225Ac’s physical characteristics and production as a potential theranostic radionuclide." Pharmaceuticals, Vol. 16 (No. 12), p. 1679, (2023).
73- R Eychenne, M Chérel, F Haddad, F Guérard, and JF Gestin, "Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”, Pharmaceutics, 2021, 13, 906." This article is licensed under a Creative Commons Attribution-NonCommercial, Vol. 3(2021).
74- Franziska Graf et al., "DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy." PloS one, Vol. 9 (No. 2), p. e88239, (2014).
75- Saman Khaled and Kathryn D Held, "Radiation biology: a handbook for teachers and students." ed: Taylor & Francis, (2012).
76- Clemens Kratochwil et al., "213 Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience." European journal of nuclear medicine and molecular imaging, Vol. 41pp. 2106-19, (2014).
77- Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Amlesh Seth, and Chandrasekhar Bal, "Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients." Theranostics, Vol. 10 (No. 20), p. 9364, (2020).
78- Maarten J van der Doelen et al., "Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy." in Urologic Oncology: Seminars and Original Investigations, (2021), Vol. 39 (No. 10): Elsevier, pp. 729. e7-29. e16.
79- Mike Sathekge et al., "225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings." European journal of nuclear medicine and molecular imaging, Vol. 50 (No. 7), pp. 2210-18, (2023).
80- Mike Sathekge et al., "225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46pp. 129-38, (2019).
81- Mahshid Kiani et al., "Recent Clinical Implications of FAPI: Imaging and Therapy." Clinical nuclear medicine, p. 10.1097, (2022).
82- Gopal B Saha, Fundamentals of nuclear pharmacy. Springer, (2004).
83- Aki Akai, Yukie Yamamura, Manabu Nonaka, and Toshio Yoshihara, "99mTcO4− accumulation in scintigraphy and expression of Na+/I− symporter in salivary gland tumors." Auris Nasus Larynx, Vol. 41 (No. 6), pp. 532-38, (2014).
84- M Nakayama, K Nakajima, and K Takahashi, "Approach to diagnosis of salivary gland disease from nuclear medicine images, in salivary glands-new approaches in diagnostics and treatment. 2017." ed: IntechOpen.
85- Samira M Sadowski et al., "Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites." Journal of Clinical Oncology, Vol. 34 (No. 6), p. 588, (2016).
86- Valentina Ambrosini et al., "68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors." Journal of Nuclear Medicine, Vol. 51 (No. 5), pp. 669-73, (2010).
87- Constantin Lapa et al., "68Ga-pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma." Theranostics, Vol. 6 (No. 3), p. 428, (2016).
88- Marco Fellner et al., "PET/CT imaging of osteoblastic bone metastases with 68 Ga-bisphosphonates: first human study." European journal of nuclear medicine and molecular imaging, Vol. 37pp. 834-34, (2010).
89- Nina Pfannkuchen et al., "Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases." Pharmaceuticals, Vol. 10 (No. 2), p. 45, (2017).
90- Averilicia Passah et al., "Evaluation of bone-seeking novel radiotracer 68 Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast." European journal of nuclear medicine and molecular imaging, Vol. 44pp. 41-49, (2017).
91- Ambreen Khawar et al., "Preliminary results of biodistribution and dosimetric analysis of [68 Ga] Ga-DOTA ZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases." Annals of nuclear medicine, Vol. 33pp. 404-13, (2019).
92- Guillaume P Nicolas et al., "Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: evaluation of sensitivity in a prospective phase II imaging study." Journal of Nuclear Medicine, (2017).
93- Jae Seon Eo and Jae Min Jeong, "Angiogenesis imaging using 68Ga-RGD PET/CT: therapeutic implications." in Seminars in Nuclear Medicine, (2016), Vol. 46: Elsevier, pp. 419-27.
94- Steve Durante et al., "Head and neck tumors angiogenesis imaging with 68 Ga-NODAGA-RGD in comparison to 18 F-FDG PET/CT: a pilot study." EJNMMI research, Vol. 10pp. 1-11, (2020).
95- Patrick M Colletti, "New Treatment Option: 223: Ra Chloride, the First Approved Unsealed α-Emitting Radiopharmaceutical." Clinical nuclear medicine, Vol. 38 (No. 9), pp. 724-25, (2013).
96- Giuseppe Boni et al., "223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: real-world experience." Tumori Journal, Vol. 104 (No. 2), pp. 128-36, (2018).
97- Emmanuel Deshayes et al., "Radium 223 dichloride for prostate cancer treatment." Drug design, development and therapy, pp. 2643-51, (2017).
98- Thomas P Thamboo, Kong‐Bing Tan, Shih‐Chang Wang, and Manuel Salto‐Tellez, "Extra‐hepatic embolisation of Y‐90 microspheres from selective internal radiation therapy (SIRT) of the liver." Pathology, Vol. 35 (No. 4), pp. 351-53, (2003).
99- Julien Edeline et al., "Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma." Clinical nuclear medicine, Vol. 40 (No. 11), pp. 851-55, (2015).
100- S Peter Kim, Claire Cohalan, Neil Kopek, and Shirin A Enger, "A guide to 90Y radioembolization and its dosimetry." Physica Medica, Vol. 68pp. 132-45, (2019).
101- I Kurilova et al., "90 Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material." Cardiovascular and interventional radiology, Vol. 41pp. 1419-27, (2018).
102- The American Thyroid Association Taskforce on Radioiodine Safety Sisson et al., "Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association." Thyroid, Vol. 21 (No. 4), pp. 335-46, (2011).
103- Jacqueline Jonklaas et al., "Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement." Thyroid, Vol. 24 (No. 12), pp. 1670-751, (2014).
104- Bryan R Haugen et al., "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer." Thyroid, Vol. 26 (No. 1), pp. 1-133, (2016).
105- Sarika Sharma, Baljinder Singh, Ashwani Koul, and Bhagwant Rai Mittal, "Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients’ pain score analysis and personalized dosimetry." Frontiers in medicine, Vol. 4p. 46, (2017).
106- Narjess Ayati et al., "Treatment efficacy of 153Sm-EDTMP for painful bone metastasis." Asia Oceania Journal of Nuclear Medicine and Biology, Vol. 1 (No. 1), p. 27, (2013).
107- ALBERTO ERNESTO HARDY PEREZ, EUGENIO TORRES GARCIA, CONSUELO ARTEAGA PEREZ, MARTHA PEDRAZA LOPEZ, ELENI MITSOURA, and KEILA ISAAC OLIVE, "Preliminary clinical experience of the systemic use of 153Sm-EDTMP as a pain palliation agent in arthrosis and as an option for bone scanning in patients with bone metastases."
108- Ana M Denis-Bacelar et al., "Phase I/II trials of 186 Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival." European journal of nuclear medicine and molecular imaging, Vol. 44pp. 620-29, (2017).
109- Daiki Kayano and Seigo Kinuya, "Current consensus on I-131 MIBG therapy." Nuclear medicine and molecular imaging, Vol. 52pp. 254-65, (2018).
110- Francesco Giammarile, Arturo Chiti, Michael Lassmann, Boudewijn Brans, and Glenn Flux, "EANM procedure guidelines for 131 I-meta-iodobenzylguanidine (131 I-mIBG) therapy." European journal of nuclear medicine and molecular imaging, Vol. 35pp. 1039-47, (2008).
111- Oliver Sartor and Ken Herrmann, "Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations." Journal of Nuclear Medicine, Vol. 63 (No. 6), pp. 823-29, (2022).
112- Ting Bu et al., "177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians." Frontiers in oncology, Vol. 12(2022).
113- Amir Karimzadeh et al., "177Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers." Journal of Nuclear Medicine, (2022).
114- John J Zaknun et al., "The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours." European journal of nuclear medicine and molecular imaging, Vol. 40pp. 800-16, (2013).
115- Clemens Kratochwil et al., "225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer." Journal of Nuclear Medicine, Vol. 57 (No. 12), pp. 1941-44, (2016).
116- Mathias Johannes Zacherl et al., "First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients." Journal of Nuclear Medicine, Vol. 62 (No. 5), pp. 669-74, (2021).
117- Eline L Hooijman et al., "Development of [225Ac] Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC." Pharmaceutics, Vol. 13 (No. 5), p. 715, (2021).
118- Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, and Chandrasekhar Bal, "Efficacy and safety of 225 Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study." European journal of nuclear medicine and molecular imaging, pp. 1-12, (2022).
119- Mengqi Shi et al., "Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists." Front. Med, Vol. 9p. 1034315, (2022).
120- Jingjing Zhang, Harshad R Kulkarni, and Richard P Baum, "225Ac-DOTATOC–Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation." Clinical nuclear medicine, Vol. 46 (No. 12), pp. 1030-31, (2021).
121- Clemens Kratochwil et al., "Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity." European journal of nuclear medicine and molecular imaging, Vol. 49 (No. 1), pp. 54-63, (2021).
2- Farid A Badria, "Radiopharmaceuticals: On-Going Research for Better Diagnosis, Therapy, Environmental, and Pharmaceutical Applications." Radiopharmaceuticals: Current Research for Better Diagnosis and Therapy, p. 3, (2022).
3- George Sgouros, Lisa Bodei, Michael R McDevitt, and Jessie R Nedrow, "Radiopharmaceutical therapy in cancer: clinical advances and challenges." Nature Reviews Drug Discovery, Vol. 19 (No. 9), pp. 589-608, (2020).
4- Filipe Boccato Payolla, Antonio Carlos Massabni, and Chris Orvig, "Radiopharmaceuticals for diagnosis in nuclear medicine: A short review." Eclética Química, Vol. 44 (No. 3), pp. 11-19, (2019).
5- Craig W Lindsley, Christa E Müller, and Salvatore Bongarzone, "Diagnostic and therapeutic radiopharmaceuticals." Vol. 5, ed: ACS Publications, (2022), pp. 835-37.
6- Teresa A O’Sullivan and Curtis G Jefferson, "A review of strategies for enhancing clarity and reader accessibility of qualitative research results." American Journal of Pharmaceutical Education, Vol. 84 (No. 1), p. 7124, (2020).
7- Vladimir Drozdovitch et al., "Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960–2010." Health physics, Vol. 108 (No. 5), pp. 520-37, (2015).
8- Buck A Rhodes and Barbara Y Croft, "Basics of radiopharmacy." (No Title), (1978).
9- Michael F L'Annunziata, Radioactivity: introduction and history, from the quantum to quarks. Elsevier, (2016).
10- Seyed K Imam, "Molecular nuclear imaging: the radiopharmaceuticals." Cancer biotherapy & radiopharmaceuticals, Vol. 20 (No. 2), pp. 163-72, (2005).
11- George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, Gabriel Andrieș, Călin Căinap, and Vasile Chiș, "Radiopharmaceuticals for PET and SPECT imaging: A literature review over the last decade." International journal of molecular sciences, Vol. 23 (No. 9), p. 5023, (2022).
12- Ora Israel et al., "Two decades of SPECT/CT–the coming of age of a technology: an updated review of literature evidence." European journal of nuclear medicine and molecular imaging, Vol. 46pp. 1990-2012, (2019).
13- Adriano Duatti, "Review on 99mTc radiopharmaceuticals with emphasis on new advancements." Nuclear medicine and biology, Vol. 92pp. 202-16, (2021).
14- Joseph Lau, Etienne Rousseau, Daniel Kwon, Kuo-Shyan Lin, François Bénard, and Xiaoyuan Chen, "Insight into the Development of PET Radiopharmaceuticals for Oncology." Cancers, Vol. 12 (No. 5), p. 1312, (2020).
15- Terence J O’Brien et al., "Comparative study of 99mTc-ECD and99mTc-HMPAO for peri-ictal SPECT: qualitative and quantitative analysis." Journal of Neurology, Neurosurgery & Psychiatry, Vol. 66 (No. 3), pp. 331-39, (1999).
16- Erhard Suess, Sigismund Huck, Hans Reither, Heide Hörtnagl, and Peter Angelberger, "Uptake mechanism of technetium-99m-d, 1-HMPAO in cell cultures of the dissociated postnatal rat cerebellum." Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, Vol. 33 (No. 1), pp. 108-14, (1992).
17- Seok Rye Choi et al., "Correlation of amyloid PET ligand florbetapir F 18 (18F-AV-45) binding with β-amyloid aggregation and neuritic plaque deposition in postmortem brain tissue." Alzheimer Disease and Associated Disorders, Vol. 26 (No. 1), p. 8, (2012).
18- Jaya Shukla and Bhagwant Rai Mittal, "Dimercaptosuccinic acid: A multifunctional cost effective agent for imaging and therapy." Indian Journal of Nuclear Medicine: IJNM: The Official Journal of the Society of Nuclear Medicine, India, Vol. 30 (No. 4), p. 295, (2015).
19- Cheng-Han Wu, Bang-Hung Yang, Yuan-Hwa Chou, Shyh-Jen Wang, and Jyh-Cheng Chen, "Effects of 99mTc-TRODAT-1 drug template on image quantitative analysis." PLoS One, Vol. 13 (No. 3), p. e0194503, (2018).
20- Vera Artiko et al., "Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC." Nuclear Medicine Review, Vol. 19 (No. 2), pp. 99-103, (2016).
21- Steven M Larson, "Mechanisms of localization of gallium-67 in tumors." in Seminars in nuclear medicine, (1978), Vol. 8: Elsevier, pp. 193-203.
22- Heinz O Hirzel et al., "Thallium-201 scintigraphy in complete left bundle branch block." The American journal of cardiology, Vol. 53 (No. 6), pp. 764-69, (1984).
23- Archi Agrawal, Venkatesh Rangarajan, Sneha Shah, Ameya Puranik, and Nilendu Purandare, "MIBG (metaiodobenzylguanidine) theranostics in pediatric and adult malignancies." The British journal of radiology, Vol. 91 (No. 1091), p. 20180103, (2018).
24- Werner Langsteger, Martin Heinisch, and Ignac Fogelman, "The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast." in Seminars in nuclear medicine, (2006), Vol. 36: Elsevier, pp. 73-92.
25- Clemens Kratochwil et al., "68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer." Journal of Nuclear Medicine, Vol. 60 (No. 6), pp. 801-05, (2019).
26- Padmaja Yalamanchili et al., "Mechanism of uptake and retention of F-18 BMS-747 158-02 in cardiomyocytes: a novel PET myocardial imaging agent." Journal of Nuclear Cardiology, Vol. 14pp. 782-88, (2007).
27- John O Prior et al., "Quantification of myocardial blood flow with 82 Rb positron emission tomography: clinical validation with 15 O-water." European journal of nuclear medicine and molecular imaging, Vol. 39pp. 1037-47, (2012).
28- Jan H Rüschoff et al., "What’s behind 68 Ga-PSMA-11 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns." European journal of nuclear medicine and molecular imaging, Vol. 48pp. 4042-53, (2021).
29- Xiang Li et al., "[68 Ga] Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery." European journal of nuclear medicine and molecular imaging, Vol. 46pp. 1616-25, (2019).
30- George Sgouros, "Radiopharmaceutical therapy." Health physics, Vol. 116 (No. 2), p. 175, (2019).
31- Attila Keresztes, Attila Borics, and Csaba Tömböly, "Therapeutic and diagnostic radiopharmaceuticals." (2015).
32- Nasir Abbas, Helen Heyerdahl, Øyvind S Bruland, Jørgen Borrebæk, Jahn Nesland, and Jostein Dahle, "Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab." EJNMMI research, Vol. 1 (No. 1), pp. 1-12, (2011).
33- Narges K Tafreshi et al., "Development of targeted alpha particle therapy for solid tumors." Molecules, Vol. 24 (No. 23), p. 4314, (2019).
34- Albert Jang, Ayse T Kendi, Geoffrey B Johnson, Thorvardur R Halfdanarson, and Oliver Sartor, "Targeted Alpha-Particle Therapy: A Review of Current Trials." International journal of molecular sciences, Vol. 24 (No. 14), p. 11626, (2023).
35- Kwamena E Baidoo, Kwon Yong, and Martin W Brechbiel, "Molecular pathways: targeted α-particle radiation therapy." Clinical Cancer Research, Vol. 19 (No. 3), pp. 530-37, (2013).
36- Matt Shirley and Paul L McCormack, "Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases." Drugs, Vol. 74pp. 579-86, (2014).
37- Fable Zustovich and Francesca Fabiani, "Therapeutic opportunities for castration-resistant prostate cancer patients with bone metastases." Critical reviews in oncology/hematology, Vol. 91 (No. 2), pp. 197-209, (2014).
38- Jon L Aro, Stephen I Dinning, Eugene Y Leung, and Lionel S Zuckier, "Safe Use of Radium-223 Dichloride (223RaCl2) Across a Wide Range of Clinical Scenarios, Incorporating a 10-year Single-Institution Radiation Safety Experience." Journal of Medical Imaging and Radiation Sciences, Vol. 50 (No. 4), pp. S36-S40, (2019).
39- Malick Bio Idrissou, Alexandre Pichard, Bryan Tee, Tibor Kibedi, Sophie Poty, and Jean-Pierre Pouget, "Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide." Pharmaceutics, Vol. 13 (No. 7), p. 980, (2021).
40- Abdelhamid H Elgazzar, The pathophysiologic basis of nuclear medicine. Springer Science & Business Media, (2006).
41- Diane S Abou et al., "Improved 223Ra Therapy with Combination Epithelial Sodium Channel Blockade." Journal of Nuclear Medicine, Vol. 62 (No. 12), pp. 1751-58, (2021).
42- Philippa J Cheetham and Daniel P Petrylak, "Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection." Oncology, Vol. 26 (No. 4), p. 330, (2012).
43- Nasim Vahidfar, Elisabeth Eppard, Saeed Farzanehfar, Anna Yordanova, Maryam Fallahpoor, and Hojjat Ahmadzadehfar, "An impressive approach in nuclear medicine: Theranostics." PET clinics, Vol. 16 (No. 3), pp. 327-40, (2021).
44- Nasim Vahidfar, Ayuob Aghanejad, Hojjat Ahmadzadehfar, Saeed Farzanehfar, and Elisabeth Eppard, "Theranostic advances in breast cancer in nuclear medicine." International journal of molecular sciences, Vol. 22 (No. 9), p. 4597, (2021).
45- Cristina Barca et al., "Expanding theranostic radiopharmaceuticals for tumor diagnosis and therapy." Pharmaceuticals, Vol. 15 (No. 1), p. 13, (2021).
46- Jonathan Strosberg et al., "Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors." New England Journal of Medicine, Vol. 376 (No. 2), pp. 125-35, (2017).
47- Ute Hennrich and Matthias Eder, "[177Lu] Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer." Pharmaceuticals, Vol. 15 (No. 10), p. 1292, (2022).
48- Irene Virgolini et al., "Procedure guidelines for pet/ct tumour imaging with 68 Ga-dota-conjugated peptides: 68 Ga-dota-toc, 68 Ga-dota-noc, 68 Ga-dota-tate." European journal of nuclear medicine and molecular imaging, Vol. 37pp. 2004-10, (2010).
49- Ute Hennrich and Martina Benešová, "[68Ga] Ga-DOTA-TOC: the first FDA-approved 68Ga-radiopharmaceutical for PET imaging." Pharmaceuticals, Vol. 13 (No. 3), p. 38, (2020).
50- Wallace Jones, Kelly Griffiths, Pedro C Barata, and Channing J Paller, "PSMA theranostics: Review of the current status of PSMA-targeted imaging and radioligand therapy." Cancers, Vol. 12 (No. 6), p. 1367, (2020).
51- Nikhil Mayor et al., "Prostate‐specific membrane antigen theranostics in advanced prostate cancer: an evolving option." BJU international, Vol. 126 (No. 5), pp. 525-35, (2020).
52- Nasim Vahidfar, Maryam Fallahpoor, Saeed Farzanehfar, Ghasemali Divband, and Hojjat Ahmadzadehfar, "Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer." Journal of Radioanalytical and Nuclear Chemistry, Vol. 322pp. 237-48, (2019).
53- Thomas Lindner, Frederik L Giesel, Clemens Kratochwil, and Sebastian E Serfling, "Radioligands targeting fibroblast activation protein (FAP)." Cancers, Vol. 13 (No. 22), p. 5744, (2021).
54- Marko Magdi Abdou Sidrak et al., "Fibroblast Activation Protein Inhibitor (FAPI)-Based Theranostics—Where We Are at and Where We Are Heading: A Systematic Review." International journal of molecular sciences, Vol. 24 (No. 4), p. 3863, (2023).
55- Liang Zhao et al., "Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review." Theranostics, Vol. 12 (No. 4), p. 1557, (2022).
56- Muhsin H Younis, Xiaoli Lan, and Weibo Cai, "PET with a 68Ga-Labeled FAPI Dimer: Moving Toward Theranostics." Journal of Nuclear Medicine, Vol. 63 (No. 6), p. 860, (2022).
57- Emran Askari, Sara Harsini, Nasim Vahidfar, Ghasemali Divband, and Ramin Sadeghi, "177Lu-EDTMP for metastatic bone pain palliation: A systematic review and meta-analysis." Cancer biotherapy & radiopharmaceuticals, Vol. 36 (No. 5), pp. 383-90, (2021).
58- José Carlos Dos Santos et al., "Development of novel PSMA ligands for imaging and therapy with copper isotopes." Journal of Nuclear Medicine, Vol. 61 (No. 1), pp. 70-79, (2020).
59- Maija Radzina et al., "Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?" EJNMMI radiopharmacy and chemistry, Vol. 8 (No. 1), p. 27, (2023).
60- Yuriko Mori, Katharina Dendl, Jens Cardinale, Clemens Kratochwil, Frederik L Giesel, and Uwe Haberkorn, "FAPI PET: fibroblast activation protein inhibitor use in oncologic and nononcologic disease." Radiology, Vol. 306 (No. 2), p. e220749, (2023).
61- Yizhen Pang et al., "PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study." Journal of Nuclear Medicine, Vol. 64 (No. 3), pp. 386-94, (2023).
62- Manish Ora et al., "Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions." Journal of Nuclear Medicine, (2023).
63- Rahul V Parghane and Sandip Basu, "PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects." Expert Review of Anticancer Therapy, Vol. 23 (No. 9), pp. 959-75, (2023).
64- Vishnu Murthy et al., "Prognostic value of end-of-treatment PSMA PET/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis." Journal of Nuclear Medicine, Vol. 64 (No. 11), pp. 1737-43, (2023).
65- Maija Radzina et al., "Accuracy of 68Ga-PSMA-11 PET/CT and multiparametric MRI for the detection of local tumor and lymph node metastases in early biochemical recurrence of prostate cancer." American Journal of Nuclear Medicine and Molecular Imaging, Vol. 10 (No. 2), p. 106, (2020).
66- Ali Afshar-Oromieh et al., "Comparison of PET imaging with a 68 Ga-labelled PSMA ligand and 18 F-choline-based PET/CT for the diagnosis of recurrent prostate cancer." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41pp. 11-20, (2014).
67- Lena Koller et al., "Preclinical Comparison of the 64Cu-and 68Ga-Labeled GRPR-Targeted Compounds RM2 and AMTG, as Well as First-in-Humans [68Ga] Ga-AMTG PET/CT." Journal of Nuclear Medicine, Vol. 64 (No. 10), pp. 1654-59, (2023).
68- Yanqing Zheng et al., "The value of targeting cxcr4 with 68ga-pentixafor pet/ct for subtyping primary aldosteronism." The Journal of Clinical Endocrinology & Metabolism, Vol. 109 (No. 1), pp. 171-82, (2024).
69- Kambiz Rahbar et al., "Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study." Journal of Nuclear Medicine, Vol. 64 (No. 4), pp. 574-78, (2023).
70- Siju C George and E James Jebaseelan Samuel, "Developments in 177Lu-based radiopharmaceutical therapy and dosimetry." Frontiers in Chemistry, Vol. 11(2023).
71- Rosalba Mansi, Guillaume Pierre Nicolas, Luigi Del Pozzo, Karim Alexandre Abid, Eric Grouzmann, and Melpomeni Fani, "Evaluation of a new 177Lu-labeled somatostatin analog for the treatment of tumors expressing somatostatin receptor subtypes 2 and 5." Molecules, Vol. 25 (No. 18), p. 4155, (2020).
72- Wael Jalloul et al., "Targeted alpha therapy: all we need to know about 225Ac’s physical characteristics and production as a potential theranostic radionuclide." Pharmaceuticals, Vol. 16 (No. 12), p. 1679, (2023).
73- R Eychenne, M Chérel, F Haddad, F Guérard, and JF Gestin, "Overview of the most promising radionuclides for targeted alpha therapy: The “hopeful eight”, Pharmaceutics, 2021, 13, 906." This article is licensed under a Creative Commons Attribution-NonCommercial, Vol. 3(2021).
74- Franziska Graf et al., "DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy." PloS one, Vol. 9 (No. 2), p. e88239, (2014).
75- Saman Khaled and Kathryn D Held, "Radiation biology: a handbook for teachers and students." ed: Taylor & Francis, (2012).
76- Clemens Kratochwil et al., "213 Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience." European journal of nuclear medicine and molecular imaging, Vol. 41pp. 2106-19, (2014).
77- Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, Madhavi Tripathi, Amlesh Seth, and Chandrasekhar Bal, "Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant prostate cancer patients." Theranostics, Vol. 10 (No. 20), p. 9364, (2020).
78- Maarten J van der Doelen et al., "Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy." in Urologic Oncology: Seminars and Original Investigations, (2021), Vol. 39 (No. 10): Elsevier, pp. 729. e7-29. e16.
79- Mike Sathekge et al., "225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings." European journal of nuclear medicine and molecular imaging, Vol. 50 (No. 7), pp. 2210-18, (2023).
80- Mike Sathekge et al., "225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study." European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46pp. 129-38, (2019).
81- Mahshid Kiani et al., "Recent Clinical Implications of FAPI: Imaging and Therapy." Clinical nuclear medicine, p. 10.1097, (2022).
82- Gopal B Saha, Fundamentals of nuclear pharmacy. Springer, (2004).
83- Aki Akai, Yukie Yamamura, Manabu Nonaka, and Toshio Yoshihara, "99mTcO4− accumulation in scintigraphy and expression of Na+/I− symporter in salivary gland tumors." Auris Nasus Larynx, Vol. 41 (No. 6), pp. 532-38, (2014).
84- M Nakayama, K Nakajima, and K Takahashi, "Approach to diagnosis of salivary gland disease from nuclear medicine images, in salivary glands-new approaches in diagnostics and treatment. 2017." ed: IntechOpen.
85- Samira M Sadowski et al., "Prospective study of 68Ga-DOTATATE positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites." Journal of Clinical Oncology, Vol. 34 (No. 6), p. 588, (2016).
86- Valentina Ambrosini et al., "68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors." Journal of Nuclear Medicine, Vol. 51 (No. 5), pp. 669-73, (2010).
87- Constantin Lapa et al., "68Ga-pentixafor-PET/CT for imaging of chemokine receptor 4 expression in glioblastoma." Theranostics, Vol. 6 (No. 3), p. 428, (2016).
88- Marco Fellner et al., "PET/CT imaging of osteoblastic bone metastases with 68 Ga-bisphosphonates: first human study." European journal of nuclear medicine and molecular imaging, Vol. 37pp. 834-34, (2010).
89- Nina Pfannkuchen et al., "Novel radiolabeled bisphosphonates for PET diagnosis and endoradiotherapy of bone metastases." Pharmaceuticals, Vol. 10 (No. 2), p. 45, (2017).
90- Averilicia Passah et al., "Evaluation of bone-seeking novel radiotracer 68 Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breast." European journal of nuclear medicine and molecular imaging, Vol. 44pp. 41-49, (2017).
91- Ambreen Khawar et al., "Preliminary results of biodistribution and dosimetric analysis of [68 Ga] Ga-DOTA ZOL: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseases." Annals of nuclear medicine, Vol. 33pp. 404-13, (2019).
92- Guillaume P Nicolas et al., "Comparison of 68Ga-OPS202 (68Ga-NODAGA-JR11) and 68Ga-DOTATOC (68Ga-Edotreotide) PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: evaluation of sensitivity in a prospective phase II imaging study." Journal of Nuclear Medicine, (2017).
93- Jae Seon Eo and Jae Min Jeong, "Angiogenesis imaging using 68Ga-RGD PET/CT: therapeutic implications." in Seminars in Nuclear Medicine, (2016), Vol. 46: Elsevier, pp. 419-27.
94- Steve Durante et al., "Head and neck tumors angiogenesis imaging with 68 Ga-NODAGA-RGD in comparison to 18 F-FDG PET/CT: a pilot study." EJNMMI research, Vol. 10pp. 1-11, (2020).
95- Patrick M Colletti, "New Treatment Option: 223: Ra Chloride, the First Approved Unsealed α-Emitting Radiopharmaceutical." Clinical nuclear medicine, Vol. 38 (No. 9), pp. 724-25, (2013).
96- Giuseppe Boni et al., "223Ra-chloride therapy in men with hormone-refractory prostate cancer and skeletal metastases: real-world experience." Tumori Journal, Vol. 104 (No. 2), pp. 128-36, (2018).
97- Emmanuel Deshayes et al., "Radium 223 dichloride for prostate cancer treatment." Drug design, development and therapy, pp. 2643-51, (2017).
98- Thomas P Thamboo, Kong‐Bing Tan, Shih‐Chang Wang, and Manuel Salto‐Tellez, "Extra‐hepatic embolisation of Y‐90 microspheres from selective internal radiation therapy (SIRT) of the liver." Pathology, Vol. 35 (No. 4), pp. 351-53, (2003).
99- Julien Edeline et al., "Glass microspheres 90Y selective internal radiation therapy and chemotherapy as first-line treatment of intrahepatic cholangiocarcinoma." Clinical nuclear medicine, Vol. 40 (No. 11), pp. 851-55, (2015).
100- S Peter Kim, Claire Cohalan, Neil Kopek, and Shirin A Enger, "A guide to 90Y radioembolization and its dosimetry." Physica Medica, Vol. 68pp. 132-45, (2019).
101- I Kurilova et al., "90 Y Resin Microspheres Radioembolization for Colon Cancer Liver Metastases Using Full-Strength Contrast Material." Cardiovascular and interventional radiology, Vol. 41pp. 1419-27, (2018).
102- The American Thyroid Association Taskforce on Radioiodine Safety Sisson et al., "Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association." Thyroid, Vol. 21 (No. 4), pp. 335-46, (2011).
103- Jacqueline Jonklaas et al., "Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement." Thyroid, Vol. 24 (No. 12), pp. 1670-751, (2014).
104- Bryan R Haugen et al., "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer." Thyroid, Vol. 26 (No. 1), pp. 1-133, (2016).
105- Sarika Sharma, Baljinder Singh, Ashwani Koul, and Bhagwant Rai Mittal, "Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients’ pain score analysis and personalized dosimetry." Frontiers in medicine, Vol. 4p. 46, (2017).
106- Narjess Ayati et al., "Treatment efficacy of 153Sm-EDTMP for painful bone metastasis." Asia Oceania Journal of Nuclear Medicine and Biology, Vol. 1 (No. 1), p. 27, (2013).
107- ALBERTO ERNESTO HARDY PEREZ, EUGENIO TORRES GARCIA, CONSUELO ARTEAGA PEREZ, MARTHA PEDRAZA LOPEZ, ELENI MITSOURA, and KEILA ISAAC OLIVE, "Preliminary clinical experience of the systemic use of 153Sm-EDTMP as a pain palliation agent in arthrosis and as an option for bone scanning in patients with bone metastases."
108- Ana M Denis-Bacelar et al., "Phase I/II trials of 186 Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival." European journal of nuclear medicine and molecular imaging, Vol. 44pp. 620-29, (2017).
109- Daiki Kayano and Seigo Kinuya, "Current consensus on I-131 MIBG therapy." Nuclear medicine and molecular imaging, Vol. 52pp. 254-65, (2018).
110- Francesco Giammarile, Arturo Chiti, Michael Lassmann, Boudewijn Brans, and Glenn Flux, "EANM procedure guidelines for 131 I-meta-iodobenzylguanidine (131 I-mIBG) therapy." European journal of nuclear medicine and molecular imaging, Vol. 35pp. 1039-47, (2008).
111- Oliver Sartor and Ken Herrmann, "Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations." Journal of Nuclear Medicine, Vol. 63 (No. 6), pp. 823-29, (2022).
112- Ting Bu et al., "177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians." Frontiers in oncology, Vol. 12(2022).
113- Amir Karimzadeh et al., "177Lu-PSMA-I&T for treatment of metastatic castration resistant prostate cancer: prognostic value of scintigraphic and clinical biomarkers." Journal of Nuclear Medicine, (2022).
114- John J Zaknun et al., "The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours." European journal of nuclear medicine and molecular imaging, Vol. 40pp. 800-16, (2013).
115- Clemens Kratochwil et al., "225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer." Journal of Nuclear Medicine, Vol. 57 (No. 12), pp. 1941-44, (2016).
116- Mathias Johannes Zacherl et al., "First clinical results for PSMA-targeted α-therapy using 225Ac-PSMA-I&T in advanced-mCRPC patients." Journal of Nuclear Medicine, Vol. 62 (No. 5), pp. 669-74, (2021).
117- Eline L Hooijman et al., "Development of [225Ac] Ac-PSMA-I&T for targeted alpha therapy according to GMP guidelines for treatment of mCRPC." Pharmaceutics, Vol. 13 (No. 5), p. 715, (2021).
118- Madhav Prasad Yadav, Sanjana Ballal, Ranjit Kumar Sahoo, and Chandrasekhar Bal, "Efficacy and safety of 225 Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study." European journal of nuclear medicine and molecular imaging, pp. 1-12, (2022).
119- Mengqi Shi et al., "Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists." Front. Med, Vol. 9p. 1034315, (2022).
120- Jingjing Zhang, Harshad R Kulkarni, and Richard P Baum, "225Ac-DOTATOC–Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation." Clinical nuclear medicine, Vol. 46 (No. 12), pp. 1030-31, (2021).
121- Clemens Kratochwil et al., "Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity." European journal of nuclear medicine and molecular imaging, Vol. 49 (No. 1), pp. 54-63, (2021).
| Files | ||
| Issue | Vol 13 No 2 (2026) | |
| Section | Systematic Review(s) | |
| DOI | https://doi.org/10.18502/fbt.v13i2.21951 | |
| Keywords | ||
| Radiopharmaceuticals Theranostics Diagnostic Therapeutic Radiotracer Radiation | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Kiani M, Farzanefar S, Mirabedian SS, Bakhshi Kashi M, Eppard E, Vahidfar N. Radiopharmaceuticals: A Brief Overview of Basic Pharmacological Parameters. Frontiers Biomed Technol. 2026;13(2):573-591.
